Trial Site Detail
Drug: |
Belzutifan |
|||
|---|---|---|---|---|
Trial: |
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Recruiting |
|||
Sarah Cannon Research Institute3322 West End Avenue Suite 900 |
Principal Investigator: |
|
|---|---|
Contact: |
Study Coordinator 615-329-7274 |
Activation Status of this Site: |
Active |
Notes about this Site: |
|
Sarah Cannon Research Institute Website: |
http://www.sarahcannonresearch.com/CustomPage.asp?PageName=Refractory%20Malignancies |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.